Discover the latest advancements in small cell lung cancer through Novotech CRO’s in-depth disease analysis. Gain valuable insights into novel therapies, ongoing clinical trials, and future ...

A new molecular imaging agent can accurately identify a crucial biomarker found among many different types of cancer. Precise ...

WEST CHESTER, PA — Molecular Targeting Technologies, Inc. (MTTI) has unveiled significant preclinical results for its ...

Researchers have used a chemical compound to light up treatment-resistant cancers on imaging scans, in a breakthrough that ...

Most non-small-cell lungcancer is caused by smoking, but your genes may also help determine your chances of getting the disease. Lung cancer is when cell growth in the lungs becomes abnormal and ...

American Cancer Society: “How is non-small cell lung cancer staged?” “Surgery for non-small cell lung cancer,” “Treatment choices by stage for non-small cell lung cancer,” “Radiation ...

The Food and Drug Administration (FDA) has approved Imfinzi ® (durvalumab), as a single agent, for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has ...

An FDA-approved drug used to treat multiple myeloma and lymphoma also shrank tumors in non-small cell lung cancer (NSCLC) ...

The U.S. Food and Drug Administration has approved AstraZeneca blockbuster drug Imfinzi to treat some adults with ...

Researchers have used a chemical compound to light up treatment-resistant cancers on imaging scans, in a breakthrough that could help medical professionals better target and treat cancer.

The study characterizes the lung cancer tumor microenvironment, linking cellular compositions to immunotherapy resistance and ...

The highly anticipated PROSPECT-Lung trial has officially opened, marking a significant step forward in the quest to improve treatment strategies for patients with resectable non-small cell lung ...